1
=
-
Becton, Dickinson and Co.
As of May 21, 2026 at 02:31 UTC
Chart
About Becton, Dickinson and Co.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
Market Statistics
Trading Metrics
How to Buy BDX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy BDX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe global nebulizer market is projected to grow from US$1.5 billion in 2025 to US$2.2 billion by 2032 at a CAGR of 5.9%. Growth is driven by rising respiratory disease prevalence, aging populations, technological advancements in mesh and smart nebulizers, and increasing adoption of home healthcare solutions. Key market segments include jet nebulizers, ultrasonic nebulizers, and mesh nebulizers across hospitals, clinics, and home settings.
The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.
The global HPV testing and Pap test market is projected to grow from USD 3.7 billion in 2025 to USD 6.5 billion by 2034, driven by rising cervical cancer prevalence, government screening initiatives, technological advancements, and the introduction of self-sampling tests. North America leads the market with 40.5% share, while Asia-Pacific emerges as a key growth hub.
The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.
Becton Dickinson (BDX) shares rose 5.9% Thursday after reporting strong Q2 fiscal 2026 results with revenue of $4.71 billion (up 5.2% YoY) and adjusted EPS of $2.90, both exceeding analyst expectations. The company raised its full-year adjusted earnings guidance to $12.52-$12.72 per share and completed a $2 billion accelerated share repurchase program.